Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02884908 · ClinicalTrials.gov registry record · Phase 3
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD
A Phase 3 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 3
- Development phase
- 57
- Enrollment target
NCT02884908 is a Phase 3 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 57 participants.
The verdict
NCT02884908, a Phase 3 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 57 participants
- Enrollment target
Study Summary
The primary study objective is to determine the efficacy of pregabalin administered orally for a period of 12 weeks in reducing risky drinking and symptoms of posttraumatic stress disorder who have selected genotypes at the gamma-amino butyric acid transporter and receptor genes. The secondary objective is to assess the safety and tolerability of pregabalin in participants with alcohol use disorder and co-occurring posttraumatic stress disorder who have selected genotypes at the gamma-amino butyric acid transporter and receptor genes. The investigators will utilize a sample of African-Americans that includes both genders and individuals with different types of trauma.
Interventions
- DRUG Pregabalin plus BBCET
- OTHER Placebo plus BBCET
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2017-07-07 |
| Est. Completion | 2022-01-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02884908
The ClinicalTrials.gov registry entry for NCT02884908 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pregabalin plus BBCET is the first listed.
NCT02884908 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02884908 about?
NCT02884908 is a clinical study titled "Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD". The primary study objective is to determine the efficacy of pregabalin administered orally for a period of 12 weeks in reducing risky drinking and symptoms of posttraumatic stress disorder who have selected genotypes at the gamma-amino butyric acid transporter and receptor genes. The secondary objec...
What is the current status of trial NCT02884908?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 57 participants. The study started on 2017-07-07. Estimated completion is 2022-01-19.
What interventions are being tested in trial NCT02884908?
The interventions under investigation include: Pregabalin plus BBCET (DRUG), Placebo plus BBCET (OTHER).
Who is sponsoring clinical trial NCT02884908?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.